Lancashire (LRE) Competitors GBX 660 +5.00 (+0.76%) As of 10/24/2025 12:44 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock LRE vs. MDC, ROAD, CCT, GEO, PRIM, EME, CCS, PHM, J, and MTHShould you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), Roadside Real Estate (ROAD), The Character Group (CCT), Georgian Mining (GEO), Primorus Investments (PRIM), Empyrean Energy (EME), Crossword Cybersecurity (CCS), Phimedix Plc (PHM.L) (PHM), Jacobs Engineering Group (J), and Mithras Investment Trust (MTH). These companies are all part of the "construction" industry. Lancashire vs. Its Competitors Mediclinic International Roadside Real Estate The Character Group Georgian Mining Primorus Investments Empyrean Energy Crossword Cybersecurity Phimedix Plc (PHM.L) Jacobs Engineering Group Mithras Investment Trust Lancashire (LON:LRE) and Mediclinic International (LON:MDC) are both construction companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Do institutionals & insiders hold more shares of LRE or MDC? 63.4% of Lancashire shares are held by institutional investors. Comparatively, 39.2% of Mediclinic International shares are held by institutional investors. 4.6% of Lancashire shares are held by insiders. Comparatively, 48.9% of Mediclinic International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer LRE or MDC? Lancashire presently has a consensus target price of GBX 652.75, indicating a potential downside of 1.10%. Given Mediclinic International's higher possible upside, analysts plainly believe Mediclinic International is more favorable than Lancashire.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lancashire 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Mediclinic International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LRE or MDC a better dividend stock? Lancashire pays an annual dividend of GBX 23.79 per share and has a dividend yield of 3.6%. Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays out 25.9% of its earnings in the form of a dividend. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has preferable earnings and valuation, LRE or MDC? Lancashire has higher earnings, but lower revenue than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLancashire£1.82B0.88£199.02M£92.007.17Mediclinic International£3.38B0.00£169M£0.23N/A Does the media favor LRE or MDC? In the previous week, Lancashire had 1 more articles in the media than Mediclinic International. MarketBeat recorded 1 mentions for Lancashire and 0 mentions for Mediclinic International. Lancashire's average media sentiment score of 0.67 beat Mediclinic International's score of 0.00 indicating that Lancashire is being referred to more favorably in the media. Company Overall Sentiment Lancashire Positive Mediclinic International Neutral Is LRE or MDC more profitable? Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.Company Net Margins Return on Equity Return on Assets Lancashire37.12% 10.76% 6.75% Mediclinic International 4.99%5.50%2.30% Which has more risk and volatility, LRE or MDC? Lancashire has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Mediclinic International has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. SummaryLancashire beats Mediclinic International on 13 of the 17 factors compared between the two stocks. Get Lancashire News Delivered to You Automatically Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRE vs. The Competition Export to ExcelMetricLancashireInsurance IndustryFinancial SectorLON ExchangeMarket Cap£1.57B£2.73B£4.95B£2.66BDividend Yield2.77%2.11%4.40%5.35%P/E Ratio7.177.1423.24400.09Price / Sales0.88185.881,377.6498,316.31Price / Cash2.172.04127.8527.90Price / Book1.081.702.167.26Net Income£199.02M£474.99M£1.22B£5.88B7 Day Performance3.45%1.43%0.94%1.07%1 Month Performance1.23%0.43%1.20%1.72%1 Year Performance2.35%12.39%38.08%111.52% Lancashire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRELancashire2.6201 of 5 starsGBX 660+0.8%GBX 652.75-1.1%+1.9%£1.57B£1.82B7.17393MDCMediclinic InternationalN/AN/AN/AN/A£3.69B£3.38B2,178.261,640ROADRoadside Real EstateN/AGBX 60+2.6%N/A+116.4%£86.21M£590K218.023,790CCTThe Character GroupN/AGBX 270-1.8%N/A+2.9%£48.34M£118.82M916.501,540Dividend IncreaseGEOGeorgian MiningN/AGBX 0.30-1.7%N/A-82.8%£14.46MN/A-343.0215,800PRIMPrimorus InvestmentsN/AGBX 4.04+6.3%N/A-4.6%£5.14M-£265K-0.2012,800Gap UpEMEEmpyrean EnergyN/AGBX 0.06-7.9%N/A-72.5%£3.32MN/A-32.2235,500Gap DownCCSCrossword CybersecurityN/AN/AN/AN/A£1.95M£4.19M-43.751,540Gap DownHigh Trading VolumePHMPhimedix Plc (PHM.L)N/AN/AN/AN/A£327KN/A-1.586,520Gap DownHigh Trading VolumeJJacobs Engineering GroupN/AN/AN/AN/A£0.00N/A0.0060,000News CoveragePositive NewsHigh Trading VolumeMTHMithras Investment TrustN/AN/AN/AN/A£0.00N/A0.001,920Gap Up Related Companies and Tools Related Companies Mediclinic International Competitors Roadside Real Estate Competitors The Character Group Competitors Georgian Mining Competitors Primorus Investments Competitors Empyrean Energy Competitors Crossword Cybersecurity Competitors Phimedix Plc (PHM.L) Competitors Jacobs Engineering Group Competitors Mithras Investment Trust Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:LRE) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lancashire Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Lancashire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.